澳大利亚养老院抗抑郁药使用趋势(2006-2019)
这项全国重复横断面研究纳入2006至2019年澳大利亚养老院65至105岁长期居民779659人,发现抗抑郁药使用率从46.1%升至58.5%,其中米氮平从8.4%升至20.9%,提示潜在超说明书使用并亟需优化干预。
要点
- 澳大利亚养老院抗抑郁药使用率从2006年46.1%升至2019年58.5%。
- 米氮平使用率从8.4%升至20.9%,是增长的主要驱动因素。
- 2019年近五分之三居民使用抗抑郁药,提示潜在超说明书使用。
核心结论
- 澳大利亚养老院抗抑郁药使用显著增加,主要由米氮平驱动,提示潜在超说明书使用并亟需优化干预。
主要发现
- 抗抑郁药总体使用率从2006年46.1%(95%CI 45.9-46.4)升至2019年58.5%(95%CI 58.3-58.8),aRR为1.02(95%CI 1.02-1.02)。
- 米氮平使用率从2006年8.4%(95%CI 8.2-8.5)升至2019年20.9%(95%CI 20.7-21.1),aRR为1.07(95%CI 1.07-1.07)。
- 抗抑郁药供应量从350.3(95%CI 347.6-353.1)升至506.0(95%CI 502.8-509.3)DDDs/1000居民日,aRR为1.03(95%CI 1.03-1.03)。
- 米氮平利用量年增长6%(aRR 1.06,95%CI 1.06-1.06)。
临床怎么用
- 老年医学科医生应关注养老院长期居住老年人的抗抑郁药使用情况,尤其米氮平增长趋势。
- 对使用抗抑郁药的居民应评估适应证,警惕潜在超说明书使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Antipsychotics have been the focus of reforms for improving the appropriateness of psychotropic medicine use in residential aged care facilities (RACFs). Comprehensive evaluation of antidepressant use in RACFs is required to inform policy and practice initiatives targeting psychotropic medicines. This study examined national trends in antidepressant use among older people living in RACFs from 2006 to 2019. DESIGN: National repeated cross-sectional study. SETTING AND PARTICIPANTS: Individuals aged 65 to 105 years who were permanent, long-term (≥100 days) residents of Australian RACFs between January 2006 and December 2019 were included. METHODS: Annual age- and sex-adjusted antidepressant prevalence rates and defined daily doses (DDDs) supplied per 1000 resident-days from 2006 to 2019 were determined. Age- and sex-adjusted prevalence rate ratios (aRRs) and 95% confidence intervals (CIs) were estimated using Poisson and negative binomial regression models. RESULTS: A total of 779,659 residents of 3371 RACFs were included (786,227,380 resident-days). Overall, antidepressant use increased from 46.1% (95% CI, 45.9-46.4) in 2006 to 58.5% (95% CI, 58.3-58.8) of residents in 2019 (aRR, 1.02; 95% CI, 1.02-1.02). Mirtazapine use increased from 8.4% (95% CI, 8.2-8.5) to 20.9% (95% CI, 20.7-21.1) from 2006 to 2019 (aRR, 1.07; 95% CI, 1.07-1.07). Antidepressant use increased from 350.3 (95% CI, 347.6-353.1) to 506.0 (95% CI, 502.8-509.3) DDDs/1000 resident-days (aRR, 1.03; 95% CI, 1.03-1.03), with mirtazapine utilization increasing by 6% annually (aRR, 1.06; 95% CI, 1.06-1.06). CONCLUSIONS AND IMPLICATIONS: This nationwide study identified a substantial increase in antidepressant use among residents of Australian RACFs, largely driven by mirtazapine. With nearly 3 in every 5 residents treated with an antidepressant in 2019, findings highlight potential off-label use and suggest that interventions to optimize care are urgently needed.
引用
- Hughes GA, Inacio MC, Rowett D, et al. National Trends in Antidepressant Use in Australian Residential Aged Care Facilities (2006-2019). J Am Med Dir Assoc. 2024. PMID: 38432647. doi:10.1016/j.jamda.2024.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。